It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.

An infection with respiratory syncytial virus (RSV) typically affects infants much harder than adults. While adults usually ...

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

TikTok, X, and Instagram are flooded with videos about a mysterious “2025 throat virus” that’s making everyone sick. The ...

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the E ...

Flu Statistics: The CDC reports that the 2025 Southern Hemisphere seasonal influenza vaccine reduced influenza-associated hospitalizations by nearly 50%. Thousands of deaths in the U.S. each year are ...

COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across various populations.

The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...

FDA reexamine infant RSV therapies with Sanofi, AstraZeneca, and Merck amid safety concerns and data review under new FDA leadership.

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

The preventive therapies would be the latest called into question under U.S. Health Secretary Robert F. Kennedy Jr., a long-time promoter of anti-vaccine views.